
Moleculin Biotech MBRX
$ 2.4
-1.6%
Annual report 2025
added 03-18-2026
Moleculin Biotech ROA Ratio 2011-2026 | MBRX
Annual ROA Ratio Moleculin Biotech
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -151.68 | -153.9 | -77.89 | -50.55 | -18.9 | -59.78 | -52.33 | -60.64 | -50.33 | -23.95 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -18.9 | -153.9 | -69.99 |
Quarterly ROA Ratio Moleculin Biotech
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -220.83 | -126.06 | -107.57 | -46.91 | -61.1 | -45.27 | -41.07 | -42.38 | -55.55 | -54.53 | -51.1 | -31.14 | -36.07 | -27.84 | -23.13 | -13.93 | -25.62 | -32.38 | -62.68 | -50.69 | -67.12 | -71.85 | -41.85 | -37.28 | -47.68 | -41.66 | -62.99 | -46.41 | -61.12 | -65.43 | -56.83 | -33.97 | -42.71 | -36.73 | -23.67 | -15.27 | -813.8 | -1603.59 | -1599.08 | -798.53 | -798.53 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -13.93 | -1603.59 | -183.46 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | ||
|
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-31.06 | $ 3.85 | 3.22 % | $ 9.26 B | ||
|
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
6.32 | $ 327.0 | -1.92 % | $ 42.8 B | ||
|
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | ||
|
I-Mab
IMAB
|
7.43 | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
-35.68 | - | 4.14 % | $ 49.1 M | ||
|
Burford Capital Limited
BUR
|
5.51 | $ 4.71 | -0.42 % | $ 766 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | ||
|
Cabaletta Bio
CABA
|
-101.68 | $ 3.52 | 3.38 % | $ 354 M | ||
|
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M | ||
|
Aligos Therapeutics
ALGS
|
-27.33 | $ 8.24 | 11.12 % | $ 81.5 M | ||
|
Allakos
ALLK
|
-76.23 | - | - | $ 28.6 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M | ||
|
Applied Therapeutics
APLT
|
-218.41 | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
-122.8 | - | -13.39 % | $ 1.45 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-1008.51 | - | -2.5 % | $ 5.88 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
6.02 | $ 21.94 | 1.2 % | $ 1.03 B | ||
|
CymaBay Therapeutics
CBAY
|
-24.24 | - | - | $ 3.45 B | ||
|
BioNTech SE
BNTX
|
65.02 | $ 100.85 | 1.39 % | $ 27.2 B | ||
|
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - | ||
|
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-103.3 | $ 3.13 | -3.52 % | $ 5.15 M | ||
|
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | ||
|
ContraFect Corporation
CFRX
|
-315.07 | - | -5.16 % | $ 5.39 M | ||
|
Galectin Therapeutics
GALT
|
-157.87 | $ 2.34 | -8.79 % | $ 150 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
-1.42 | $ 1.4 | -10.0 % | $ 360 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
-52.23 | $ 4.22 | -0.59 % | $ 451 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-3.73 | $ 24.2 | -1.55 % | $ 3.08 B | ||
|
Grifols, S.A.
GRFS
|
1.38 | $ 8.59 | -1.1 % | $ 6.83 B | ||
|
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | ||
|
BioDelivery Sciences International
BDSI
|
26.14 | - | -4.8 % | $ 255 M | ||
|
Autolus Therapeutics plc
AUTL
|
-48.81 | $ 1.53 | 2.68 % | $ 407 M | ||
|
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | ||
|
BeiGene, Ltd.
BGNE
|
3.5 | - | 0.49 % | $ 251 B | ||
|
Checkpoint Therapeutics
CKPT
|
-752.78 | - | - | $ 169 M | ||
|
Caladrius Biosciences
CLBS
|
-57.1 | - | -16.75 % | $ 25.8 M | ||
|
AVROBIO
AVRO
|
12.03 | - | 1083.1 % | $ 745 M | ||
|
Clearside Biomedical
CLSD
|
-95.49 | - | - | $ 25.3 M | ||
|
Celldex Therapeutics
CLDX
|
-44.38 | $ 33.66 | -0.62 % | $ 2.24 B | ||
|
bluebird bio
BLUE
|
-34.23 | - | - | $ 546 M |